Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.04
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.04
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.60 - $15.57
Previous CloseN/A
Volume45.37K
Average Volume (3M)338.78K
Market Cap
$279.42M
Enterprise Value$114.75M
Total Cash (Recent Filing)$118.64M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Aug 06, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.79
Shares Outstanding29,381,514
10 Day Avg. Volume639,902
30 Day Avg. Volume338,784
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue64.65
Enterprise Value/Gross Profit-10.41
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$33.83Price Target Upside380.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$549.50K
Bulls Say, Bears Say
Bulls Say
Strategic Licensing Alliance (in‑vivo CAR‑T)The WestGene licensing deal creates a structural shift from ex vivo to in vivo CAR‑T approaches, potentially simplifying manufacturing and accelerating clinical translation. That broadens Cartesian’s platform, reduces manufacturing complexity for select programs, and can lower long‑term cost and time to market.
Secured Credit Facility Extends RunwayA committed senior secured facility materially extends financing runway into 2028, reducing near‑term dilution risk and enabling execution of late‑stage trials and regulatory filings. Access to non‑dilutive capital supports planned catalysts and gives management time to de‑risk programs before further fundraising.
Clear Near‑term Clinical Catalyst TimelineA defined sequence of pivotal and mid‑stage readouts into 2027 provides structural value drivers: positive efficacy/safety data could validate the platform, support regulatory filings, and attract partners. Predictable catalyst timing helps prioritize resources and long‑term strategic planning.
Bears Say
Persistent Heavy Cash Burn And LossesSustained negative operating and free cash flow at scale indicates reliance on external financing for core operations and trials. Over multiple quarters this magnifies funding risk, forces prioritization of programs, and increases the probability of dilution or restrictive financing terms absent material clinical or partnership breakthroughs.
Negative Equity And Limited Financial FlexibilitySubstantial negative equity reflects accumulated deficits that constrain strategic options: limited capacity for unsecured borrowing, higher cost of capital, and elevated dilution risk when raising equity. This structural weakness can limit investment in pipeline expansion absent third‑party partnerships or milestone funding.
Leadership And Governance Turnover RiskMid‑senior clinical and board departures create execution and oversight risk during pivotal development phases. Loss of institutional knowledge can delay trial execution, regulatory preparations, or strategic decisions, and may pressure hiring or succession efforts that materially affect long‑term program delivery.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.60 and its highest was $15.57 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $279.42M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.59.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 29,381,514 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -2.158%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (380.59% Upside)
$33.83 (380.59% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.12%
12-Months-Change
Fundamentals
Return on Equity
194.13%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the advancement and discovery of nanoparticle-based immunomodulatory drugs. These innovative therapeutics are designed to both treat and prevent a variety of human ailments. The company's leading gene therapy initiative, SEL-302, is currently undergoing Phase I clinical trials, with the goal of improving the efficacy of treatment for methylmalonic acidemia. Its product pipeline also features biologic therapies, including SEL-212, which is now in Phase III clinical trials for the management of chronic refractory gout. Furthermore, Selecta is developing candidate therapies specifically aimed at various IgA-mediated conditions, such as IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. Beyond these, the company is progressing gene therapies to address a range of disorders, including Pompe disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorders, and other autoimmune conditions. Selecta's research also encompasses tolerogenic therapies, which are developed to target and mitigate autoimmune diseases. The firm has forged strategic alliances and licensing agreements with a diverse group of partners, notably Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Established in 2007, Selecta Biosciences, Inc. maintains its corporate headquarters in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$33.83
▲(380.59% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
44.17% Insiders
7.33% Mutual Funds
3.32% Other Institutional Investors
42.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---